FAQ

incomplete Freund's adjuvant

Known as: Freund's incomplete adjuvant, IFA 
A mixture of oil and water that is combined with a specific antigen to boost the immune response to that antigen. It is being studied in… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1966-2017
05019662017

Related topics

Related topics

17 relations
AFP gene hepatocellular carcinoma vaccine/Montanide ISA-51CRL 1005/gp100 antigen/Montanide ISA-51/tyrosinase peptideCRL 1005/gp100 antigen/incomplete Freund's adjuvant/tyrosinase peptideCytotoxic T-Lymphocytes
(More)

Broader (2)

Freund's AdjuvantLipids

Narrower (1)

montanide ISA 51

Related mentions per year

Related mentions per year

1937-2018
19401960198020002020
incomplete Freund's adjuvant
Lipids
Cytotoxic T-Lymphocytes
Freund's Adjuvant
T-Cell Activation
T-Lymphocyte

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.
In experimental tumor immunotherapy, incomplete Freund's adjuvant (IFA) has been considered as the "gold standard" for T-cell… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants.
Neutrophils modulated Ag presentation following immunization with Ags in CFA or IFA or alum. The neutrophils had an important… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements
BACKGROUND It is now emerging that for vaccines against a range of diseases including influenza, malaria and HIV, the induction… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.
Therapeutic vaccination trials, in which patients with cancer were vaccinated with minimal CTL peptide in oil-in-water… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
The induction of potent CD8+ T cell responses by vaccines to fight microbes or tumors remains a major challenge, as many… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2002
2002
Inhibitory effects of incomplete Freund's adjuvant on experimental autoimmune encephalomyelitis.
Freund's incomplete adjuvant (IFA), an aqueous/oil emulsion that is widely used in combination with antigenic proteins and… (More)
Is this relevant?
2000
2000
Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant.
Injection of autoantigens in IFA has been one of the most effective ways of preventing experimental, T cell-mediated, autoimmune… (More)
  • table I
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response.
Traditionally, protein Ags have been injected in CFA (oil with inactivated mycobacteria) to induce immunity and with IFA (oil… (More)
  • figure 1
  • figure 2
  • figure 3
  • table I
  • figure 4
Is this relevant?
1998
1998
Adjuvant activity of incomplete Freund's adjuvant.
The water-in-oil emulsion adjuvants developed by Jules Freund and coworkers have been, and continue to be, used in research and… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity
Synthetic oligodeoxynucleotides (ODN) that contain unmethylated CpG motifs (CpG ODN) induce macrophages to secrete IL-12, which… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?